Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Non-Current Deffered Revenue: 2016-2024

Historic Non-Current Deffered Revenue for Wave Life Sciences (WVE) over the last 9 years, with Dec 2024 value amounting to $6.1 million.

  • Wave Life Sciences' Non-Current Deffered Revenue fell 36.83% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 36.83%. This contributed to the annual value of $6.1 million for FY2024, which is 60.91% down from last year.
  • Latest data reveals that Wave Life Sciences reported Non-Current Deffered Revenue of $6.1 million as of FY2024, which was down 60.91% from $15.6 million recorded in FY2023.
  • Wave Life Sciences' Non-Current Deffered Revenue's 5-year high stood at $79.8 million during FY2022, with a 5-year trough of $6.1 million in FY2024.
  • In the last 3 years, Wave Life Sciences' Non-Current Deffered Revenue had a median value of $15.6 million in 2023 and averaged $33.8 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 86.78% in 2021, then slumped by 80.44% in 2023.
  • Over the past 5 years, Wave Life Sciences' Non-Current Deffered Revenue (Yearly) stood at $41.5 million in 2020, then soared by 86.78% to $77.5 million in 2021, then grew by 2.96% to $79.8 million in 2022, then plummeted by 80.44% to $15.6 million in 2023, then tumbled by 60.91% to $6.1 million in 2024.